GSK further extends its product portfolio in the Middle East and North Africa
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m).
Lu AA24530 shows positive results in major depressive disorder phase II study
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD).
Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Details
- Category: Pfizer
Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Details
- Category: Clinical Trials
Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
Bayer files patent infringement lawsuit against Teva
- Details
- Category: Bayer
Bayer Schering Pharma AG, Germany and Bayer HealthCare Pharmaceuticals Inc. together with Schering Corporation have filed a patent infringement lawsuit in the U.S. Federal Court in the District of Delaware against Teva Pharmaceuticals USA, Inc. and Teva
Pharmaceutical Industries, Ltd.
IRESSA (Gefitinib) Receives Marketing Authorisation in Europe
- Details
- Category: AstraZeneca
AstraZeneca announced that the European Commission has granted marketing authorisation for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK (epidermal growth factor receptor-tyrosine kinase) across all lines of therapy.
Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer
- Details
- Category: Pfizer
Pfizer Inc announced the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC).
More Pharma News ...
- AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
- Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
- Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities
- Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia
- Sutent Significantly Improved Progression-Free Survival
- GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
- New biological therapy Ilaris® approved in US